"On October 24, 2016, the U.S. Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co., Inc.) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FD"...
None.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 10/24/2016
Additional Gilotrif Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.